Molecular Biomarker and Programmed Death-Ligand 1 Expression Testing in Patients With Advanced Stage Non-small Cell Lung Cancer Across North Carolina Community Hospitals

Precision medicine in advanced non-small cell lung cancer (NSCLC) requires molecular biomarker testing in patients with nonsquamous and select patients with squamous histologies, and programmed death-ligand 1 (PD-L1) testing in both. What are rates of molecular and PD-L1 biomarker testing in patient...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Chest 2021-09, Vol.160 (3), p.1121-1130
Hauptverfasser:	Rivera, M. Patricia, Charlot, Marjory, Durham, Danielle D., Throneburg, Allison, Lane, Lindsay M., Perera, Pasangi, Samulski, Teresa D., Henderson, Louise M.
Format:	Artikel
Sprache:	eng
Schlagworte:	B7-H1 Antigen - analysis B7-H1 Antigen - genetics Biomarkers, Tumor - analysis Biomarkers, Tumor - genetics Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - epidemiology Carcinoma, Non-Small-Cell Lung - genetics Critical Care Medicine Female Gene Expression Profiling - methods Gene Expression Regulation, Neoplastic General & Internal Medicine Guideline Adherence - standards Health Services Misuse - prevention & control Humans Life Sciences & Biomedicine Lung Neoplasms - diagnosis Lung Neoplasms - epidemiology Lung Neoplasms - genetics Male Middle Aged molecular biomarkers Mutation non-small cell lung cancer PD-L1 Pharmacogenomic Testing - methods Pharmacogenomic Testing - statistics & numerical data Precision Medicine - methods Procedures and Techniques Utilization - statistics & numerical data Respiratory System Science & Technology Sociodemographic Factors United States - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!